361540
GSK-3β Inhibitor I
The GSK-3β Inhibitor I, also referenced under CAS 327036-89-5, controls the biological activity of GSK-3β. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
別名:
GSK-3β Inhibitor I, TDZD-8, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C10H10N2O2S
CAS番号:
分子量:
222.26
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white to off-white
solubility
DMSO: 10 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
S1N(C(=O)N(C1=O)Cc2ccccc2)C
InChI
1S/C10H10N2O2S/c1-11-9(13)12(10(14)15-11)7-8-5-3-2-4-6-8/h2-6H,7H2,1H3
InChI key
JDSJDASOXWCHPN-UHFFFAOYSA-N
General description
A cell-permeable, thiadiazolidinone (TDZD) analog that acts as a highly selective, non-ATP-competitive inhibitor of GSK-3β (IC50 = 2 µM). Inhibits Flt-3 and PKC activities (IC50 = 673 nM and 1.4-5.5 µM, respectively). Does not significantly affect the activities of Cdk1/cyclin B, CK-II, PKA, or PKC (IC50 >100 µM). Shown to inhibit collagen- and thrombin-induced platelet aggregation.
A thiadiazolidinone (TDZD) analog that acts as a highly selective, non-ATP competitive inhibitor of GSK-3β (IC50 = 2 µM). Inhibits Flt-3 and PKC activities (IC50 = 673 nM and 1.4-5.5 µM, respectively). Does not significantly affect the activities of Cdk-1/cyclin B, CK-II, and PKA, (IC50 >100 µM). Binds to the active site of GSK-3β.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Gsk-3β
Gsk-3β
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM, 673 nM, 1.4-5.5 µM, against GSK-3β, Flt-3, and PKC activities, respectively
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Guzman, M.L., et al. 2007. Blood110, 4436.
Barry, F.A., et al. 2003. FEBS Lett.553, 173.
Martinez, A., et al. 2002. J. Med. Chem.45, 1292.
Barry, F.A., et al. 2003. FEBS Lett.553, 173.
Martinez, A., et al. 2002. J. Med. Chem.45, 1292.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
一体何が起きているの？
WGK 3
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
361540-1.1ML: + 361540-MG: + 361540-5MG:
jan